Ocular delivery of therapeutics to address diseases of the posterior segment of the eye such as age-related macular degeneration, diabetic retinopathy, posterior uveitis and retinitis, presents numerous problems as existing injection systems are too unwieldy to be able to effectively target this region. Therefore, therapeutic ocmpounds designed for such diseases are often injected into the vitreus of the eye, requiring very large doses and repeated injections that can lead to diffuse, off-target effects. Periocular injections and implants are both highly invasive and lead to similar non-targeted effects. Emory's Dr. Edelhauser found that the problems with previous ocular drug delivery systems could be overcome by infusing the compounds into what has been termed the 'suprachoiroidal space'. In collaboration with colleagues at the Georgia Institute of Technology, Dr. Edelhauser has shown that using microneedle technology to effect this delivery provides immediate, highly specific delivery to the posterior segment. Clearside Biomedical is founded to develop a microneedle based system to deliver both existing therapeutics for ocular disorders more effectively, and to provide targeted delivery of new ocular therapeutics to the posterior segment.